Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled “Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial,”1 published online May 26, 2020, there was an error in Figure 3. In panel C, the CINRG DNHS line should be 0.42 at the week 13 visit and 0.74 at the week 25 visit. This article was corrected online.
Error in Figure. JAMA Neurol. 2020;77(8):1040. doi:10.1001/jamaneurol.2020.2025
Monkeypox Resource Center